Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Jaapan - inglise - すりの適正使用協議会 RAD-AR Council, Japan

nippon boehringer ingelheim co., ltd. - tiotropium bromide hydrate; olodaterol hydrochloride - inhalation solution

Jaapan - inglise - すりの適正使用協議会 RAD-AR Council, Japan

nippon boehringer ingelheim co., ltd. - tiotropium bromide hydrate; olodaterol hydrochloride - inhalation

Kanada - inglise - Health Canada

boehringer ingelheim (canada) ltd ltee - tiotropium (tiotropium bromide monohydrate) - capsule - 18mcg - tiotropium (tiotropium bromide monohydrate) 18mcg - antimuscarinics antispasmodics

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

a-s medication solutions - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was

Kanada - inglise - Health Canada

boehringer ingelheim (canada) ltd ltee - tiotropium (tiotropium bromide monohydrate) - solution - 2.5mcg - tiotropium (tiotropium bromide monohydrate) 2.5mcg - antimuscarinics antispasmodics

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: srivasso respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). srivasso respimat is indicated for the prevention of copd exacerbations.,asthma: srivasso respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: esovynd respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). esovynd respimat is indicated for the prevention of copd exacerbations.,asthma: esovynd respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

a-s medication solutions - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tiotropium bromide monohydrate, quantity: 0.0225 mg (equivalent: tiotropium, qty 0.018 mg) - inhalation, powder for - excipient ingredients: lactose monohydrate - tiocip is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). tiocip is indicated for the prevention of copd exacerbations.